Human adipose stem cell and ASC-derived cardiac progenitor cellular therapy improves outcomes in a murine model of myocardial infarction

Davy, Philip; Lye, Kevin D.; Mathews, Juanita; Owens, Jesse B.; Chow, Alice; Wong, Livingston; Moisyadi, Stefan; Allsopp, Richard

doi:10.2147/sccaa.s86925

Cited by 8 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the derivation of iPSCs provide autologous pluripotent stem cells, salient difficulties related to cell retention, engraftment, tumorigenesis 3 , and ventricular arrhythmia 4,5 in the ischemic myocardium remain as one of the major challenges for their clinical translation. Extensive studies using various stem cells, including hESCs 6 and iPSCs 7,8 , mesenchymal stem cells (MSCs) 9,10 , adipose stem cells (ASCs) 11–13 , and cardiac progenitor cells (CPCs) 14–16 have been attempted. All these approaches have their own unique benefits and limitations.…”

mentioning

confidence: 99%

Exosomes Generated From iPSC-Derivatives

Jung

Yang

2017

Circulation Research

146

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death in modern society. The adult heart innately lacks the capacity to repair and regenerate the damaged myocardium from ischemic injury. Limited understanding of cardiac tissue repair process hampers the development of effective therapeutic solutions to treat CVD such as ischemic cardiomyopathy. In recent years, rapid emergence of induced pluripotent stem cells (iPSC) and iPSC-derived cardiomyocytes (iCM) presents a valuable opportunity to replenish the functional cells to the heart. The therapeutic effects of iPSC-derived cells have been investigated in many preclinical studies. However, the underlying mechanisms of iPSC-derived cell therapy are still unclear and limited engraftment of iCMs are well known. One facet of their mechanism is the paracrine effect of the transplanted cells. Microvesicles such as exosomes secreted from the iCMs exert protective effects by transfering the endogenous molecules to salvage the injured neighboring cells by regulating apoptosis, inflammation, fibrosis and angiogenesis. In this review, we will focus on the current advances in the exosomes from iPSC-derivatives and discuss their therapeutic potential in the treatment of CVD.

show abstract

mentioning

confidence: 99%

Exosomes Generated From iPSC-Derivatives

Jung

Yang

2017

Circulation Research

146

View full text Add to dashboard Cite

show abstract

“…At 1 month post-transplant, mice transplanted with iCPs and adipose derived stem cells showed higher myocardial capillary densities. All three samples showed a decrease in infarct size compared to the control or untreated sample; however the greatest reduction was seen in those transplanted with iCPs, which were derived from adipose tissue stem cells [ 53 ].…”

Section: Resultsmentioning

confidence: 99%

Therapeutic use of stem cells for cardiovascular disease

Faiella

Atoui

2016

Clinical & Translational Med

View full text Add to dashboard Cite

Stem cell treatments are a desirable therapeutic option to regenerate myocardium and improve cardiac function after myocardial infarction. Several different types of cells have been explored, each with their own benefits and limitations. Induced pluripotent stem cells possess an embryonic-like state and therefore have a high proliferative capacity, but they also pose a risk of teratoma formation. Mesenchymal stem cells have been investigated from both bone marrow and adipose tissue. Their immunomodulatory characteristics may permit the use of allogeneic cells as universal donor cells in the future. Lastly, studies have consistently shown that cardiac stem cells are better able to express markers of cardiogenesis compared to other cell types, as well improve cardiac function. The ideal source of stem cells depends on multiple factors such as the ease of extraction/isolation, effectiveness of engraftment, ability to differentiate into cardiac lineages and effect on cardiac function. Although multiple studies highlight the benefits and limitations of each cell type and reinforce the successful potential use of these cells to regenerate damaged myocardium, more studies are needed to directly compare cells from various sources. It is interesting to note that research using stem cell therapies is also expanding to treat other cardiovascular diseases including non-ischemic cardiomyopathies.

show abstract

“…At 1 month post‐transplant, mice transplanted with ICPs and adipose derived stem cells showed higher myocardial capillary densities. All three samples showed a decrease in infarct size compared to the control or untreated sample; however, the greatest reduction was seen in those samples transplanted with ICPs that were derived from adipose tissue stem cells . AD‐MSCs also have immunomodulatory properties.…”

Section: Adipose Tissue‐derived Mscs (Ad‐mscs)mentioning

confidence: 96%

Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction

Shafei

Ali

Ghanem

et al. 2017

The Journal of Gene Medicine

132

View full text Add to dashboard Cite

For decades, mesenchymal stem (MSCs) cells have been used for cardiovascular diseases as regenerative therapy. This review is an attempt to summarize the types of MSCs involved in myocardial infarction (MI) therapy, as well as its possible mechanisms effects, especially the paracrine one in MI focusing on the studies (human and animal) conducted within the last 10 years. Recently, reports showed that MSC therapy could have infarct-limiting effects after MI in both experimental and clinical trials. In this context, various types of MSCs can help cardiac regeneration by either revitalizing the cardiac stem cells or revascularizing the arteries and veins of the heart. Furthermore, MSCs could produce paracrine growth factors that increase the survival of nearby cardiomyocytes, as well as increase angiogenesis through recruitment of stem cell from bone marrow or inducing vessel growth from existing capillaries. Recent research suggests that the paracrine effects of MSCs could be mediated by extracellular vesicles including exosomes. Exosomal microRNAs (miRNAs) released by MSCs are promising therapeutic hotspot target for MI. This could be attributed to the role of miRNA in cardiac biology, including cardiac regeneration, stem cell differentiation, apoptosis, neovascularization, cardiac contractility and cardiac remodeling. Furthermore, gene-modified MSCs could be a recent promising therapy for MI to enhance the paracrine effects of MSCs, including better homing and effective cell targeted tissue regeneration. Although MSC therapy has achieved considerable attention and progress, there are critical challenges that remains to be overcome to achieve the most effective successful cell-based therapy in MI.

show abstract

Human adipose stem cell and ASC-derived cardiac progenitor cellular therapy improves outcomes in a murine model of myocardial infarction

Cited by 8 publications

References 51 publications

Exosomes Generated From iPSC-Derivatives

Exosomes Generated From iPSC-Derivatives

Therapeutic use of stem cells for cardiovascular disease

Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction

Contact Info

Product

Resources

About